Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $7.50.

A number of research analysts have weighed in on the company. William Blair initiated coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They issued an “outperform” rating on the stock. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target on the stock. Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 30th. They set an “equal weight” rating and a $5.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, October 19th.

Zentalis Pharmaceuticals Stock Down 3.8%

ZNTL stock opened at $1.78 on Friday. The stock has a market capitalization of $127.57 million, a P/E ratio of -0.91 and a beta of 1.91. The firm has a 50-day simple moving average of $2.87 and a 200-day simple moving average of $3.43. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, analysts expect that Zentalis Pharmaceuticals will post -2.15 earnings per share for the current year.

Insider Activity

In related news, major shareholder Group Walters bought 4,335,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the purchase, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 3.80% of the stock is owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. 5AM Venture Management LLC acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $19,147,378. BlackRock Inc. acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at $18,205,000. Bank of America Corp DE purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $5,406,000. Primecap Management Co. CA purchased a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $4,643,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter worth about $3,676,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.